Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus METHYLPREDNISOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus METHYLPREDNISOLONE.
DEXASPORIN vs METHYLPREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
None Documented
None Documented
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Deslanoside
"Methylprednisolone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethylprednisolone + Acetyldigitoxin
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination
Category C
Category D/X
Corticosteroid/Antibiotic Combination
Corticosteroid
"Methylprednisolone may decrease the cardiotoxic activities of Acetyldigitoxin."